Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Sanyal AJ, Kaplan LM, Frias JP, et al
GLP-1 RAs have also been suggested to be nephroprotective [10], even though conflicting data on renal sodium and water handling have been reported [10,11,12]
Use within 60 days of opening
Adverse Reactions in Seven Pooled 12-Week Controlled Trials In seven pooled 12-week, double-blind, randomized, placebo-controlled trials, 993 patients received 140 mg of REPATHA subcutaneously every 2 weeks and 1059 patients received 420 mg of REPATHA subcutaneously monthly
Because of both the potential for HIV-1 infection transmission and serious adverse reactions in nursing infants, mothers receiving tesamorelin should be instructed not to human milk-feed
In addition, the decision to start treatment with tesamorelin should be considered carefully based on the increased background risk of malignancies in HIV-positive patients
